

Keyword index

Acetylcholine

Ca²⁺ channel; HI-6; HLö-7; Toxogonin; Oxime; Phosphorylation; Protein kinase inhibitor; Soman (Aas, P. (301) 59)

Adenosine

Adenosine A_{2A} receptor; ZM 241385; Pharmacology, in vivo (Keddie, J.R. (301) 107)

Adenosine A_{2A} receptor

Adenosine; ZM 241385; Pharmacology, in vivo (Keddie, J.R. (301) 107)

Adrenoceptor agonist

Pain; Inflammation; Adrenoceptor antagonist; Formalin test (Hong, Y. (301) 41)

Adrenoceptor antagonist

Pain; Inflammation; Adrenoceptor agonist; Formalin test (Hong, Y. (301) 41)

Allosteric binding site

GABA_A receptor, recombinant; [³H]Flunitrazepam; [³H]Muscimol; [³⁵S]TBPS ([³⁵S]*t*-butylbicyclopophosphorothionate) (Zezula, J. (301) 207)

Analgesia

Dynorphin; Opioid; Δ⁹-Tetrahydrocannabinol; SR-141,716 A; Nornalorphimine (Reche, I. (301) 75)

Anthraquinone

Nitric oxide (NO); Senna; Cascara; Laxative; Intestinal secretion (Izzo, A.A. (301) 137)

Antisense

Immobility behaviour; Forced swim test; S-Oligodeoxynucleotide; Glucocorticoid receptor; RU38486; Central nervous system (Korte, S.M. (301) 19)

Apamin

Neurotensin; Peristalsis; Small intestine, guinea-pig (Ohashi, H. (301) 129)

Area postrema

Dopamine D₃ receptor; *R*-(+)-7-OH-DPAT (*R*-(+)-7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin); Emesis; (Ferret) (Yoshikawa, T. (301) 143)

Benzodiazepine tolerance

Medial vestibular nucleus; GABA receptor; Isoguvacine (Hutchinson, M.A. (301) 83)

Binding, in vitro

Dopamine carrier, neuronal; Ion dependence; K⁺ gradient (Héron, C. (301) 195)

Biperiden

Budipine; Muscarinic; NMDA (*N*-methyl-D-aspartate); Parkinsonism (Klockgether, T. (301) 67)

Brain, hamster

2-[¹²⁵I]MCA-NAT (2-[¹²⁵I]iodo-5-methoxy-carbonylamino-*N*-acetyl-tryptamine); Melatonin ML₂ receptor; Melatonin; Kidney; Testes; 2-[¹²⁵I]iodomelatonin (Molinari, E.J. (301) 159)

Brain, human

Imidazoline I₂ receptor; Extrapyramidal disorder (Reynolds, G.P. (301) R19)

Budipine

Biperiden; Muscarinic; NMDA (*N*-methyl-D-aspartate); Parkinsonism (Klockgether, T. (301) 67)

Ca²⁺ channel

Acetylcholine; HI-6; HLö-7; Toxogonin; Oxime; Phosphorylation; Protein kinase inhibitor; Soman (Aas, P. (301) 59)

Neuromuscular transmission; Suramin; P₂ purinoceptor; Non-depolarizing neuromuscular relaxant (Henning, R.H. (301) 91)

Lymphocyte; PN 200-110; Radioligand binding; Immune function; (Human) (Ricci, A. (301) 189)

Ca²⁺ channel antagonist

Vascular relaxation; Negative inotropic action; Negative chronotropic action; Ca²⁺ current, L-type; NB-818 (Hattori, Y. (301) 99)

Ca²⁺ current, L-type

Ca²⁺ channel antagonist; Vascular relaxation; Negative inotropic action; Negative chronotropic action; NB-818 (Hattori, Y. (301) 99)

Cascara

Nitric oxide (NO); Senna; Anthraquinone; Laxative; Intestinal secretion (Izzo, A.A. (301) 137)

Central nervous system

Immobility behaviour; Forced swim test; Antisense; S-Oligodeoxynucleotide; Glucocorticoid receptor; RU38486 (Korte, S.M. (301) 19)

Cerebral cortical neuron

Nitric oxide (NO); Peroxynitrite; GABA (γ-aminobutyric acid) release; Superoxide (Ohkuma, S. (301) 179)

CNQX (6-cyano-7-nitroquinoxaline-2,3-dione)

Glutamate; Turning; Striatum; Tetrodotoxin; *cis*-Flupenthixol (Smith, I.D. (301) 7)

Desensitization

PAF (platelet-activating factor); Spontaneously hypertensive rat (SHR); Renal hypertensive rat (RHR); GTP-binding protein (Kamata, K. (301) 121)

Digoxin

Inotropic drug; Heart failure; K⁺ channel, ATP-sensitive; Papillary muscle; Milrinone (Kocić, I. (301) 115)

Dopamine

Ethanol; 5-HT (5-hydroxytryptamine, serotonin); Microdialysis; Ventral tegmental area (Yan, Q.-S. (301) 49)

Dopamine carrier, neuronal

Binding, in vitro; Ion dependence; K⁺ gradient (Héron, C. (301) 195)

Dopamine D₃ receptor

R-(+)-7-OH-DPAT (*R*-(+)-7-hydroxy-2-(*N,N*-di-*n*-propylamino)tetralin); Emesis; Area postrema; (Ferret) (Yoshikawa, T. (301) 143)

Dopamine D₄ receptor

Raclopride (Helmeste, D. (301) R1)

Dopamine hD₂₁ receptor

Dopamine hD_{4.4} receptor; Intrinsic activity (Lahti, R.A. (301) R11)

Dopamine hD_{4.4} receptor

Dopamine hD₂₁ receptor; Intrinsic activity (Lahti, R.A. (301) R11)

Dorsal skin

Sympathetic nerve; 6-Hydroxydopamine; Mast cell (Cambridge, H. (301) 151)

Drug discrimination

Nicotine; Mecamylamine; Methyllaconitine (Brioni, J.D. (301) 1)

Dynorphin

Analgesia; Opioid; Δ^9 -Tetrahydrocannabinol; SR-141,716 A; Norbinaltorphimine (Reche, I. (301) 75)

Emesis

Dopamine D₃ receptor; *R*-(+)-7-OH-DPAT (*R*-(+)-7-hydroxy-2-(*N,N*-di-*n*-propylamino)tetralin); Area postrema; (Ferret) (Yoshikawa, T. (301) 143)

Ethanol

Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Microdialysis; Ventral tegmental area (Yan, Q.-S. (301) 49)

Extrapyramidal disorder

Imidazoline I₂ receptor; Brain, human (Reynolds, G.P. (301) R19)

[³H]Flunitrazepam

GABA_A receptor, recombinant; [³H]Muscimol; [³⁵S]TBPS ([³⁵S]*t*-butylbicyclophosphorothionate); Allosteric binding site (Zezula, J. (301) 207)

cis-Flupenthixol

Glutamate; Turning; Striatum; Tetrodotoxin; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione) (Smith, I.D. (301) 7)

Forced swim test

Immobility behaviour; Antisense; S-Oligodeoxynucleotide; Glucocorticoid receptor; RU38486; Central nervous system (Korte, S.M. (301) 19)

Formalin test

Pain; Inflammation; Adrenoceptor agonist; Adrenoceptor antagonist (Hong, Y. (301) 41)

GABA (γ -aminobutyric acid) release

Nitric oxide (NO); Peroxynitrite; Superoxide; Cerebral cortical neuron (Ohkuma, S. (301) 179)

GABA receptor

Medial vestibular nucleus; Benzodiazepine tolerance; Isoguvacine (Hutchinson, M.A. (301) 83)

GABA_A receptor, recombinant

[³H]Flunitrazepam; [³H]Muscimol; [³⁵S]TBPS ([³⁵S]*t*-butylbicyclophosphorothionate); Allosteric binding site (Zezula, J. (301) 207)

Glucocorticoid receptor

Immobility behaviour; Forced swim test; Antisense; S-Oligodeoxynucleotide; RU38486; Central nervous system (Korte, S.M. (301) 19)

Glutamate

Turning; Striatum; Tetrodotoxin; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); *cis*-Flupenthixol (Smith, I.D. (301) 7)

Glutamate receptor, metabotropic

Long-term potentiation; Mutant mouse (Bordi, F. (301) R15)

GTP-binding protein

PAF (platelet-activating factor); Desensitization; Spontaneously hypertensive rat (SHR); Renal hypertensive rat (RHR) (Kamata, K. (301) 121)

Heart failure

Inotropic drug; K⁺ channel, ATP-sensitive; Papillary muscle; Digoxin; Milrinone (Kocić, I. (301) 115)

HL-6

Acetylcholine; Ca²⁺ channel; HL δ -7; Toxogonin; Oxime; Phosphorylation; Protein kinase inhibitor; Soman (Aas, P. (301) 59)

HL δ -7

Acetylcholine; Ca²⁺ channel; HL-6; Toxogonin; Oxime; Phosphorylation; Protein kinase inhibitor; Soman (Aas, P. (301) 59)

5-HT (5-hydroxytryptamine, serotonin)

Ethanol; Dopamine; Microdialysis; Ventral tegmental area (Yan, Q.-S. (301) 49)

5-HT_{2c} receptor

Quinpirole; Normethylclozapine; Parkinson's disease (Fox, S. (301) 27)

5-HT_{1A} receptor, human

PET (positron emission tomography); [*carbonyl*-¹¹C]WAY-100635 (Pike, V.W. (301) R5)

6-Hydroxydopamine

Sympathetic nerve; Mast cell; Dorsal skin (Cambridge, H. (301) 151)

Hypercholesterolemia

Nitric oxide (NO); Sphincter of Oddi (Szilvassy, Z. (301) R17)

Imidazoline I₂ receptor

Brain, human; Extrapyramidal disorder (Reynolds, G.P. (301) R19)

Immobility behaviour

Forced swim test; Antisense; S-Oligodeoxynucleotide; Glucocorticoid receptor; RU38486; Central nervous system (Korte, S.M. (301) 19)

Immune function

Lymphocyte; Ca²⁺ channel; PN 200-110; Radioligand binding; (Human) (Ricci, A. (301) 189)

Inflammation

Pain; Adrenoceptor agonist; Adrenoceptor antagonist; Formalin test (Hong, Y. (301) 41)

Inotropic drug

Heart failure; K⁺ channel, ATP-sensitive; Papillary muscle; Digoxin; Milrinone (Kocić, I. (301) 115)

Intestinal secretion

Nitric oxide (NO); Senna; Cascara; Anthraquinone; Laxative (Izzo, A.A. (301) 137)

Intrinsic activity

Dopamine hD₂₁ receptor; Dopamine hD_{4.4} receptor (Lahti, R.A. (301) R11)

2-[¹²⁵I]Iodomelatonin

2-[¹²⁵I]MCA-NAT (2-[¹²⁵I]iodo-5-methoxy-carbonylamino-*N*-acetyltryptamine); Melatonin ML₂ receptor; Melatonin; Brain, hamster; Kidney; Testes (Molinari, E.J. (301) 159)

Ion dependence

Dopamine carrier, neuronal; Binding, in vitro; K⁺ gradient (Héron, C. (301) 195)

Isoguvacine

Medial vestibular nucleus; Benzodiazepine tolerance; GABA receptor (Hutchinson, M.A. (301) 83)

Isoprenoid

3T3-L1 cell; Lovastatin (Nishio, E. (301) 203)

K⁺ channel, ATP-sensitive

Inotropic drug; Heart failure; Papillary muscle; Digoxin; Milrinone (Kocić, I. (301) 115)

K⁺ gradient

Dopamine carrier, neuronal; Binding, in vitro; Ion dependence (Héron, C. (301) 195)

Kidney

2-[¹²⁵I]MCA-NAT (2-[¹²⁵I]iodo-5-methoxy-carbonylamino-*N*-acetyltryptamine); Melatonin ML₂ receptor; Melatonin; Brain, hamster; Testes; 2-[¹²⁵I]Iodomelatonin (Molinari, E.J. (301) 159)

Laxative

Nitric oxide (NO); Senna; Cascara; Anthraquinone; Intestinal secretion (Izzo, A.A. (301) 137)

Long-term potentiation

Mutant mouse; Glutamate receptor, metabotropic (Bordi, F. (301) R15)

Lovastatin

3T3-L1 cell; Isoprenoid (Nishio, E. (301) 203)

Lymphocyte

Ca²⁺ channel; PN 200-110; Radioligand binding; Immune function; (Human) (Ricci, A. (301) 189)

Mast cell

Sympathetic nerve; 6-Hydroxydopamine; Dorsal skin (Cambridge, H. (301) 151)

2-[¹²⁵I]MCA-NAT (2-[¹²⁵I]iodo-5-methoxy-carbonylamino-*N*-acetyltryptamine)

Melatonin ML₂ receptor; Melatonin; Brain, hamster; Kidney; Testes; 2-[¹²⁵I]Iodomelatonin (Molinari, E.J. (301) 159)

Mecamylamine

Nicotine; Drug discrimination; Methyllycaconitine (Brioni, J.D. (301) 1)

Medial vestibular nucleus

Benzodiazepine tolerance; GABA receptor; Isoguvacine (Hutchinson, M.A. (301) 83)

Melatonin

2-[¹²⁵I]MCA-NAT (2-[¹²⁵I]iodo-5-methoxy-carbonylamino-*N*-acetyltryptamine); Melatonin ML₂ receptor; Brain, hamster; Kidney; Testes; 2-[¹²⁵I]Iodomelatonin (Molinari, E.J. (301) 159)

Melatonin ML₂ receptor

2-[¹²⁵I]MCA-NAT (2-[¹²⁵I]iodo-5-methoxy-carbonylamino-*N*-acetyltryptamine); Melatonin; Brain, hamster; Kidney; Testes; 2-[¹²⁵I]Iodomelatonin (Molinari, E.J. (301) 159)

Methyllycaconitine

Nicotine; Drug discrimination; Mecamylamine (Brioni, J.D. (301) 1)

Microdialysis

Ethanol; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Ventral tegmental area (Yan, Q.-S. (301) 49)

Milrinone

Inotropic drug; Heart failure; K⁺ channel, ATP-sensitive; Papillary muscle; Digoxin (Kocić, I. (301) 115)

Muscarinic

Biperiden; Budipine; NMDA (*N*-methyl-D-aspartate); Parkinsonism (Klockgether, T. (301) 67)

[³H]Muscimol

GABA_A receptor, recombinant; [³H]Flunitrazepam; [³⁵S]TBPS ([³⁵S]-butylbicyclophosphorothionate); Allosteric binding site (Zezula, J. (301) 207)

Mutant mouse

Long-term potentiation; Glutamate receptor, metabotropic (Bordi, F. (301) R15)

Naltrexone

Opiate detoxification; Withdrawal syndrome (Muntoni, A.L. (301) R9)

NB-818

Ca²⁺ channel antagonist; Vascular relaxation; Negative inotropic action; Negative chronotropic action; Ca²⁺ current, L-type (Hattori, Y. (301) 99)

Negative chronotropic action

Ca²⁺ channel antagonist; Vascular relaxation; Negative inotropic action; Ca²⁺ current, L-type; NB-818 (Hattori, Y. (301) 99)

Negative inotropic action

Ca²⁺ channel antagonist; Vascular relaxation; Negative chronotropic action; Ca²⁺ current, L-type; NB-818 (Hattori, Y. (301) 99)

Nervous system

Opioid receptor; Steroid; Neuroblastoma (Maggi, R. (301) 169)

Neuroblastoma

Opioid receptor; Steroid; Nervous system (Maggi, R. (301) 169)

Neuromuscular transmission

Suramin; P₂ purinoceptor; Non-depolarizing neuromuscular relaxant; Ca²⁺ channel (Henning, R.H. (301) 91)

Neurotensin

Peristalsis; Small intestine, guinea-pig; Apamin (Ohashi, H. (301) 129)

- Nicotine**
Drug discrimination; Mecamylamine; Methyllaconitine (Brioni, J.D. (301) 1)
- Nitric oxide (NO)**
Senna; Cascara; Anthraquinone; Laxative; Intestinal secretion (Izzo, A.A. (301) 137)
- Peroxynitrite; GABA (γ -aminobutyric acid) release; Superoxide; Cerebral cortical neuron (Ohkuma, S. (301) 179)
- Hypercholesterolemia; Sphincter of Oddi (Szilvassy, Z. (301) R17)
- NMDA (*N*-methyl-D-aspartate)**
Biperiden; Budipine; Muscarinic; Parkinsonism (Klockgether, T. (301) 67)
- Non-depolarizing neuromuscular relaxant**
Neuromuscular transmission; Suramin; P₂ purinoceptor; Ca²⁺ channel (Henning, R.H. (301) 91)
- Nor-binaltorphimine**
Analgesia; Dynorphin; Opioid; Δ^9 -Tetrahydrocannabinol; SR-141,716 A (Reche, I. (301) 75)
- Normethylclozapine**
5-HT_{2c} receptor; Quinpirole; Parkinson's disease (Fox, S. (301) 27)
- R-(+)-7-OH-DPAT (*R*-(+)-7-hydroxy-2-(*N,N*-di-*n*-propylamino)tetralin)**
Dopamine D₃ receptor; Emesis; Area postrema; (Ferret) (Yoshikawa, T. (301) 143)
- S-Oligodeoxynucleotide**
Immobility behaviour; Forced swim test; Antisense; Glucocorticoid receptor; RU38486; Central nervous system (Korte, S.M. (301) 19)
- Opiate**
(+)-Pentazocine; σ Site; Red nucleus; Substantia nigra (Matsumoto, R.R. (301) 31)
- Opiate detoxification**
Withdrawal syndrome; Naltrexone (Muntoni, A.L. (301) R9)
- Opioid**
Analgesia; Dynorphin; Δ^9 -Tetrahydrocannabinol; SR-141,716 A; Nor-binaltorphimine (Reche, I. (301) 75)
- Opioid receptor**
Steroid; Nervous system; Neuroblastoma (Maggi, R. (301) 169)
- Oxime**
Acetylcholine; Ca²⁺ channel; HI-6; HLö-7; Toxogonin; Phosphorylation; Protein kinase inhibitor; Soman (Aas, P. (301) 59)
- PAF (platelet-activating factor)**
Desensitization; Spontaneously hypertensive rat (SHR); Renal hypertensive rat (RHR); GTP-binding protein (Kamata, K. (301) 121)
- Pain**
Inflammation; Adrenoceptor agonist; Adrenoceptor antagonist; Formalin test (Hong, Y. (301) 41)
- Papillary muscle**
Inotropic drug; Heart failure; K⁺ channel, ATP-sensitive; Digoxin; Milrinone (Kocić, I. (301) 115)
- Parkinsonism**
Biperiden; Budipine; Muscarinic; NMDA (*N*-methyl-D-aspartate) (Klockgether, T. (301) 67)
- Parkinson's disease**
5-HT_{2c} receptor; Quinpirole; Normethylclozapine (Fox, S. (301) 27)
- (+)-Pentazocine**
Opiate; σ Site; Red nucleus; Substantia nigra (Matsumoto, R.R. (301) 31)
- Peristalsis**
Neurotensin; Small intestine, guinea-pig; Apamin (Ohashi, H. (301) 129)
- Peroxynitrite**
Nitric oxide (NO); GABA (γ -aminobutyric acid) release; Superoxide; Cerebral cortical neuron (Ohkuma, S. (301) 179)
- PET (positron emission tomography)**
5-HT_{1A} receptor, human; [*carbonyl*-¹¹C]WAY-100635 (Pike, V.W. (301) R5)
- Pharmacology, in vivo**
Adenosine; Adenosine A_{2A} receptor; ZM 241385 (Keddie, J.R. (301) 107)
- Phosphorylation**
Acetylcholine; Ca²⁺ channel; HI-6; HLö-7; Toxogonin; Oxime; Protein kinase inhibitor; Soman (Aas, P. (301) 59)
- PN 200-110**
Lymphocyte; Ca²⁺ channel; Radioligand binding; Immune function; (Human) (Ricci, A. (301) 189)
- P₂ purinoceptor**
Neuromuscular transmission; Suramin; Non-depolarizing neuromuscular relaxant; Ca²⁺ channel (Henning, R.H. (301) 91)
- Protein kinase inhibitor**
Acetylcholine; Ca²⁺ channel; HI-6; HLö-7; Toxogonin; Oxime; Phosphorylation; Soman (Aas, P. (301) 59)
- Quinpirole**
5-HT_{2c} receptor; Normethylclozapine; Parkinson's disease (Fox, S. (301) 27)
- Raclopride**
Dopamine D₄ receptor (Helmeste, D. (301) R1)
- Radioligand binding**
Lymphocyte; Ca²⁺ channel; PN 200-110; Immune function; (Human) (Ricci, A. (301) 189)
- Red nucleus**
Opiate; (+)-Pentazocine; σ Site; Substantia nigra (Matsumoto, R.R. (301) 31)
- Renal hypertensive rat (RHR)**
PAF (platelet-activating factor); Desensitization; Spontaneously hypertensive rat (SHR); GTP-binding protein (Kamata, K. (301) 121)
- RU38486**
Immobility behaviour; Forced swim test; Antisense; S-Oligodeoxynucleotide; Glucocorticoid receptor; Central nervous system (Korte, S.M. (301) 19)

Senna

Nitric oxide (NO); Cascara; Anthraquinone; Laxative; Intestinal secretion (Izzo, A.A. (301) 137)

 σ Site

Opiate; (+)-Pentazocine; Red nucleus; Substantia nigra (Matsumoto, R.R. (301) 31)

Small intestine, guinea-pig

Neurotensin; Peristalsis; Apamin (Ohashi, H. (301) 129)

Soman

Acetylcholine; Ca^{2+} channel; HI-6; HLö-7; Toxogonin; Oxime; Phosphorylation; Protein kinase inhibitor (Aas, P. (301) 59)

Sphincter of Oddi

Nitric oxide (NO); Hypercholesterolemia (Szilvassy, Z. (301) R17)

Spontaneously hypertensive rat (SHR)

PAF (platelet-activating factor); Desensitization; Renal hypertensive rat (RHR); GTP-binding protein (Kamata, K. (301) 121)

SR-141,716 A

Analgesia; Dynorphin; Opioid; Δ^9 -Tetrahydrocannabinol; Nor-binaltorphimine (Reche, I. (301) 75)

[^{35}S]TBPS ([^{35}S]-butylbicyclophosphorothionate)

GABA_A receptor, recombinant; [^3H]Flunitrazepam; [^3H]Muscimol; Allosteric binding site (Zezula, J. (301) 207)

Steroid

Opioid receptor; Nervous system; Neuroblastoma (Maggi, R. (301) 169)

Striatum

Glutamate; Turning; Tetrodotoxin; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); *cis*-Flupenthixol (Smith, I.D. (301) 7)

Substantia nigra

Opiate; (+)-Pentazocine; σ Site; Red nucleus (Matsumoto, R.R. (301) 31)

Superoxide

Nitric oxide (NO); Peroxynitrite; GABA (γ -aminobutyric acid) release; Cerebral cortical neuron (Ohkuma, S. (301) 179)

Suramin

Neuromuscular transmission; P₂ purinoceptor; Non-depolarizing neuromuscular relaxant; Ca^{2+} channel (Henning, R.H. (301) 91)

Sympathetic nerve

6-Hydroxydopamine; Mast cell; Dorsal skin (Cambridge, H. (301) 151)

Testes

2-[^{125}I]MCA-NAT (2-[^{125}I]iodo-5-methoxy-carbonylamino-*N*-acetyltryptamine); Melatonin ML₂ receptor; Melatonin; Brain, hamster; Kidney; 2-[^{125}I]Iodomelatonin (Molinari, E.J. (301) 159)

 Δ^9 -Tetrahydrocannabinol

Analgesia; Dynorphin; Opioid; SR-141,716 A; Nor-binaltorphimine (Reche, I. (301) 75)

Tetrodotoxin

Glutamate; Turning; Striatum; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); *cis*-Flupenthixol (Smith, I.D. (301) 7)

3T3-L1 cell

Lovastatin; Isoprenoid (Nishio, E. (301) 203)

Toxogonin

Acetylcholine; Ca^{2+} channel; HI-6; HLö-7; Oxime; Phosphorylation; Protein kinase inhibitor; Soman (Aas, P. (301) 59)

Turning

Glutamate; Striatum; Tetrodotoxin; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); *cis*-Flupenthixol (Smith, I.D. (301) 7)

Vascular relaxation

Ca^{2+} channel antagonist; Negative inotropic action; Negative chronotropic action; Ca^{2+} current, L-type; NB-818 (Hattori, Y. (301) 99)

Ventral tegmental area

Ethanol; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Microdialysis (Yan, Q.-S. (301) 49)

[*carbonyl*- ^{11}C]WAY-100635

5-HT_{1A} receptor, human; PET (positron emission tomography) (Pike, V.W. (301) R5)

Withdrawal syndrome

Opiate detoxification; Naltrexone (Muntoni, A.L. (301) R9)

ZM 241385

Adenosine; Adenosine A_{2A} receptor; Pharmacology, in vivo (Keddie, J.R. (301) 107)